Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-SUPREME: ALG-000184 vs tenofovir disoproxil fumarate in untreated chronic hepatitis B
2025-521178-33-00Phase 2Authorised
- Sponsor
- Aligos Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of pevifoscorvir in Chronic Hepatitis B (CHB) (4 arms), sponsored by Aligos Therapeutics. Planned start Dec 2025; status: authorised.
02
Drugs
pevifoscorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2025-521178-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521178-33-00.